SHW
70
2
FLR
48
3
ACN
70
5
HUM
48
2
PG
50
2
LRCX
46
-2
ABT
57
-5
EQR
60
6
UHS
54
-4
DVA
72
-3
SCHW
65
-2
FLS
76
-2
WDC
38
-3
SIG
47
-2
DD
61
4
KHC
17
4
DFS
67
-3
MAT
38
-3
MU
32
-6
EXR
59
4
SHW
70
2
FLR
48
3
ACN
70
5
HUM
48
2
PG
50
2
LRCX
46
-2
ABT
57
-5
EQR
60
6
UHS
54
-4
DVA
72
-3
SCHW
65
-2
FLS
76
-2
WDC
38
-3
SIG
47
-2
DD
61
4
KHC
17
4
DFS
67
-3
MAT
38
-3
MU
32
-6
EXR
59
4
Financhill
Back

Pliant Therapeutics 10K Form

Sell
45

PLRX
Pliant Therapeutics

Last Price:
12.85
Seasonality Move:
15.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLRX News And Ratings

See the #1 stock for the next 7 days that we like better than PLRX

PLRX Financial Statistics

Sales & Book Value

Annual Sales: $1.58M
Cash Flow: $-33.17M
Price / Cash Flow: 0
Annual Sales: $5.68
Price / Book: 2.43

Profitability

EPS (TTM): -3.34000
Net Income (TTM): $-201.68M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Pliant Therapeutics Earnings Forecast

Key Pliant Therapeutics Financial Ratios

  • The Research & Development expenses have been 8,088.42% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of PLRX is -10,211.14% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Pliant Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PLRX
CUSIP: 729139
Website: pliantrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PLRX Technical Analysis vs Fundamental Analysis

Sell
45
Pliant Therapeutics (PLRX) is a Sell

Is Pliant Therapeutics a Buy or a Sell?